The Latin America, Middle East and Africa Cluster Headache Market should witness market growth of 7.8% CAGR during the forecast period (2022-2028).
The cycle of a headache might be shortened by using prescription drugs. These may lessen the intensity of the headaches. Verapamil, lithium carbonate, divalproex sodium, calcium channel blockers, melatonin, and topiramate are possible treatments. In addition, a new preventative treatment is a monoclonal antibody against the calcitonin gene-related peptide (CGRP). If necessary, cluster headaches have been treated surgically in the past.The use of gentle electrical stimulation on the neck is one approach. Another inserts a medical device through the top gums to produce electrical stimulation.
A rise in the introduction of different monoclonal antibodies for cluster headaches and an increase in the number of novel medications being tested in clinical trials by significant firms are expected to benefit the market's expansion. Also, it is projected that an increase in the number of cluster headache drugs in development would fuel market growth.
Saudi ArabiaPharmaceuticals’ mission is to accelerate the development of the region's manufacturing cluster and transition to more complex goods with an emphasis on those crucial for national security. With the total net worth of $120 billion and an excellent export prospect, the Saudi pharmaceutical industry is one of the fastest-growing in the world today. The Saudi pharmaceutical sector grew by over 5% CAGR in 2018 to reach 8.2 billion dollars in sales. Up to 2025, the industryis anticipated to expand at a 5% annual pace to reach $10 Bn.The substantial investment and the growing number of initiatives by the government to develop the pharmaceutical sector will provide innovative and enhanced treatment options for the cluster headache, which will propel the market growth in the LAMEA.
The Brazil market dominated the LAMEA Cluster Headache Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $8.6 Million by 2028. The Argentina market is experiencing a CAGR of 8.3% during (2022-2028). Additionally, The UAE market would display a CAGR of 7.5% during (2022-2028).
Based on Distribution channel, the market is segmented into Drug Stores & Retail Pharmacies, Hospital Pharmacies, and Others. Based on Type, the market is segmented Episodic, and Chronic. Based on Drug Class, the market is segmented into Triptans, Calcium Channel Blockers, Ergot Derivatives, and Others. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Dr. Reddy’s Laboratories Ltd., Novartis AG, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., GlaxoSmithKline PLC (GSK), Pfizer, Inc., Fresenius SE & Co. KGaA, Eli Lilly And Company, Grünenthal GmbH, and Arrotex Pharmaceuticals Pty Limited.
The cycle of a headache might be shortened by using prescription drugs. These may lessen the intensity of the headaches. Verapamil, lithium carbonate, divalproex sodium, calcium channel blockers, melatonin, and topiramate are possible treatments. In addition, a new preventative treatment is a monoclonal antibody against the calcitonin gene-related peptide (CGRP). If necessary, cluster headaches have been treated surgically in the past.The use of gentle electrical stimulation on the neck is one approach. Another inserts a medical device through the top gums to produce electrical stimulation.
A rise in the introduction of different monoclonal antibodies for cluster headaches and an increase in the number of novel medications being tested in clinical trials by significant firms are expected to benefit the market's expansion. Also, it is projected that an increase in the number of cluster headache drugs in development would fuel market growth.
Saudi ArabiaPharmaceuticals’ mission is to accelerate the development of the region's manufacturing cluster and transition to more complex goods with an emphasis on those crucial for national security. With the total net worth of $120 billion and an excellent export prospect, the Saudi pharmaceutical industry is one of the fastest-growing in the world today. The Saudi pharmaceutical sector grew by over 5% CAGR in 2018 to reach 8.2 billion dollars in sales. Up to 2025, the industryis anticipated to expand at a 5% annual pace to reach $10 Bn.The substantial investment and the growing number of initiatives by the government to develop the pharmaceutical sector will provide innovative and enhanced treatment options for the cluster headache, which will propel the market growth in the LAMEA.
The Brazil market dominated the LAMEA Cluster Headache Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $8.6 Million by 2028. The Argentina market is experiencing a CAGR of 8.3% during (2022-2028). Additionally, The UAE market would display a CAGR of 7.5% during (2022-2028).
Based on Distribution channel, the market is segmented into Drug Stores & Retail Pharmacies, Hospital Pharmacies, and Others. Based on Type, the market is segmented Episodic, and Chronic. Based on Drug Class, the market is segmented into Triptans, Calcium Channel Blockers, Ergot Derivatives, and Others. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Dr. Reddy’s Laboratories Ltd., Novartis AG, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., GlaxoSmithKline PLC (GSK), Pfizer, Inc., Fresenius SE & Co. KGaA, Eli Lilly And Company, Grünenthal GmbH, and Arrotex Pharmaceuticals Pty Limited.
Scope of the Study
By Distribution channel
- Drug Stores & Retail Pharmacies
- Hospital Pharmacies
- Others
By Type
- Episodic
- Chronic
By Drug Class
- Triptans
- Calcium Channel Blockers
- Ergot Derivatives
- Others
By Country
- Brazil
- Argentina
- UAE
- Saudi Arabia
- South Africa
- Nigeria
- Rest of LAMEA
Key Market Players
List of Companies Profiled in the Report:
- Dr.Reddy’s Laboratories Ltd.
- Novartis AG
- Sun Pharmaceutical Industries Ltd.
- Teva Pharmaceutical Industries Ltd.
- GlaxoSmithKline PLC (GSK)
- Pfizer, Inc.
- Fresenius SE & Co. KGaA
- Eli Lilly And Company
- Grünenthal GmbH
- Arrotex Pharmaceuticals Pty Limited
Unique Offerings
- Exhaustive coverage
- The highest number of Market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 LAMEA Cluster Headache Market, by Distribution channel
1.4.2 LAMEA Cluster Headache Market, by Type
1.4.3 LAMEA Cluster Headache Market, by Drug Class
1.4.4 LAMEA Cluster Headache Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market composition & scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. LAMEA Cluster Headache Market by Distribution channel
3.1 LAMEA Drug Stores & Retail Pharmacies Market by Country
3.2 LAMEA Hospital Pharmacies Market by Country
3.3 LAMEA Others Market by Country
Chapter 4. LAMEA Cluster Headache Market by Type
4.1 LAMEA Episodic Market by Country
4.2 LAMEA Chronic Market by Country
Chapter 5. LAMEA Cluster Headache Market by Drug Class
5.1 LAMEA Triptans Market by Country
5.2 LAMEA Calcium Channel Blockers Market by Country
5.3 LAMEA Ergot Derivatives Market by Country
5.4 LAMEA Others Market by Country
Chapter 6. LAMEA Cluster Headache Market by Country
6.1 Brazil Cluster Headache Market
6.1.1 Brazil Cluster Headache Market by Distribution channel
6.1.2 Brazil Cluster Headache Market by Type
6.1.3 Brazil Cluster Headache Market by Drug Class
6.2 Argentina Cluster Headache Market
6.2.1 Argentina Cluster Headache Market by Distribution channel
6.2.2 Argentina Cluster Headache Market by Type
6.2.3 Argentina Cluster Headache Market by Drug Class
6.3 UAE Cluster Headache Market
6.3.1 UAE Cluster Headache Market by Distribution channel
6.3.2 UAE Cluster Headache Market by Type
6.3.3 UAE Cluster Headache Market by Drug Class
6.4 Saudi Arabia Cluster Headache Market
6.4.1 Saudi Arabia Cluster Headache Market by Distribution channel
6.4.2 Saudi Arabia Cluster Headache Market by Type
6.4.3 Saudi Arabia Cluster Headache Market by Drug Class
6.5 South Africa Cluster Headache Market
6.5.1 South Africa Cluster Headache Market by Distribution channel
6.5.2 South Africa Cluster Headache Market by Type
6.5.3 South Africa Cluster Headache Market by Drug Class
6.6 Nigeria Cluster Headache Market
6.6.1 Nigeria Cluster Headache Market by Distribution channel
6.6.2 Nigeria Cluster Headache Market by Type
6.6.3 Nigeria Cluster Headache Market by Drug Class
6.7 Rest of LAMEA Cluster Headache Market
6.7.1 Rest of LAMEA Cluster Headache Market by Distribution channel
6.7.2 Rest of LAMEA Cluster Headache Market by Type
6.7.3 Rest of LAMEA Cluster Headache Market by Drug Class
Chapter 7. Company Profiles
7.1 Dr. Reddy’s Laboratories Ltd.
7.1.1 Company Overview
7.1.2 Financial Analysis
7.1.3 Segmental and Regional Analysis
7.1.4 Research & Development Expense
7.2 Novartis AG
7.2.1 Company Overview
7.2.2 Financial Analysis
7.2.3 Segmental and Regional Analysis
7.2.4 Research & Development Expense
7.3 Sun Pharmaceutical Industries Ltd.
7.3.1 Company Overview
7.3.2 Financial Analysis
7.3.3 Regional & Segmental Analysis
7.3.4 Research & Development Expenses
7.4 Teva Pharmaceutical Industries Ltd.
7.4.1 Company Overview
7.4.2 Financial Analysis
7.4.3 Regional Analysis
7.4.4 Research & Development Expenses
7.5 GlaxoSmithKline PLC (GSK)
7.5.1 Company Overview
7.5.2 Financial Analysis
7.5.3 Segmental and Regional Analysis
7.5.4 Research & Development Expense
7.6 Pfizer, Inc.
7.6.1 Company Overview
7.6.2 Financial Analysis
7.6.3 Regional & Segmental Analysis
7.6.4 Research & Development Expense
7.7 Fresenius SE & Co. KGaA
7.7.1 Company Overview
7.7.2 Financial Analysis
7.7.3 Segmental and Regional Analysis
7.7.4 Research & Development Expenses
7.8 Eli Lilly And Company
7.8.1 Company Overview
7.8.2 Financial Analysis
7.8.3 Regional Analysis
7.8.4 Research & Development Expenses
7.9 Grünenthal GmbH
7.9.1 Company Overview
7.9.2 Financial Analysis
7.9.3 Segmental and Regional Analysis
7.9.4 Research & Development Expenses
7.10. Arrotex Pharmaceuticals Pty Limited
7.10.1 Company Overview
Companies Mentioned
- Dr. Reddy’s Laboratories Ltd.
- Novartis AG
- Sun Pharmaceutical Industries Ltd.
- Teva Pharmaceutical Industries Ltd.
- GlaxoSmithKline PLC (GSK)
- Pfizer, Inc.
- Fresenius SE & Co. KGaA
- Eli Lilly And Company
- Grünenthal GmbH
- Arrotex Pharmaceuticals Pty Limited
Methodology
LOADING...
